Intellia Therapeutics, Inc. NTLA
10.55 USD -0.86 (-7.54%)
At closeNov 12, 2026, 5:27 PM EST
10.65 +0.10 +0.95%
After hours · Nov 12, 5:27 PM ET
10.46 Day range 11.06
7.95 52-week range 18.48
- YTD
- +17.35%
- 1 year
- +11.17%
News
globenewswire.com Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
seekingalpha.com Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack…
zacks.com Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
zacks.com Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
benzinga.com Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M Estimate Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.80) by 15.19 percent. This is a 1.09 percent increase over losses…
globenewswire.com Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and…
benzinga.com Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the…
benzinga.com Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8 Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.
benzinga.com Intellia Therapeutics Q2 2026 Earnings Call Transcript Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
benzinga.com Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13 Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.
benzinga.com HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
benzinga.com Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the…- benzinga.com Intellia Therapeutics Enters Into $400M Non-Dilutive Senior Secured Term Loan Facility With OrbiMed Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it…
benzinga.com Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting? Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and ARKW are betting on next.- benzinga.com Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
- benzinga.com Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24 Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.
- benzinga.com Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses…
benzinga.com This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.- benzinga.com Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform to Underperform and announces $9 price target.
benzinga.com Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.- benzinga.com Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17 Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.
benzinga.com Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED) Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.
benzinga.com Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% after beating earnings & revenue estimates. Other big gainers included QURE, CLPT, JLHL, BRAI, LZB,…- benzinga.com Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
- benzinga.com Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.
benzinga.com Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory outlook.- benzinga.com HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
- benzinga.com Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously…
- benzinga.com Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Breaking Oral Presentation At EAACI Annual Congress 2026 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that…
- benzinga.com Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026 Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.Late-Breaking Oral Presentation Details:Title: HAELO, a Phase 3,…
- benzinga.com Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17 Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Perform and raises the price target from $13 to $17.
benzinga.com Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts updated their ratings on top companies. For full list of changes, including upgrades/downgrades, see our analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $25 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $30 to $25.
benzinga.com Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49 Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $58 to $49.- benzinga.com Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.
- benzinga.com Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of…
- benzinga.com Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of…
benzinga.com Cathie Wood Trims Chip Exposure, Adds To AI Platforms—ETF Investors Watch Positioning Cathie Wood trims chip exposure and adds AI platform and biotech bets, offering ETF investors insight into shifting AI positioning.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lower-than-expected Q1 results. O-i Glass, Rocky Brands, and other stocks also down in pre-market…
benzinga.com Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Potential to buy TGT stock, analysts say. Photo via Shutterstock
benzinga.com GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19,…
benzinga.com Earnings Scheduled For February 26, 2026